Table 4.
Demographic and disease characteristics of patients with Crohn’s disease by bowel urgency status and treatment experience.
| TT-naïve | 1L-TT | TT-exp | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Variable | No BU (n = 533) |
BU (n = 110) |
P-value | No BU (n = 868) |
BU (n = 126) |
P-value | No BU (n = 344) |
BU (n = 60) |
P-value |
| Physician-reported | |||||||||
| Age, mean (SD) | 39.1 (13.0) | 37.8 (13.1) | .326 (t-test) | 38.9 (13.9) | 40.0 (13.0) | .371 (t-test) | 41.4 (12.7) | 44.7 (14.1) | .070 (t-test) |
| Sex, male, n (%) | 283 (53.1) | 62 (56.4) | .600 (FE) | 475 (54.7) | 59 (46.8) | .104 (FE) | 190 (55.2) | 30 (50.0) | .484 (FE) |
| BMI, mean (SD) | 24.0 (3.5) | 23.4 (2.9) | .057 (t-test) | 24.3 (4.1) | 24.0 (3.9) | .570 (t-test) | 24.3 (4.2) | 23.9 (3.5) | .590 (t-test) |
| Smoking status, n | 495 | 103 | .036 (CH) | 835 | 117 | .041 (CH) | 327 | 59 | .584 (CH) |
| Current smoker, n (%) | 88 (17.8) | 28 (27.2) | 153 (18.3) | 22 (18.8) | 62 (19.0) | 14 (23.7) | |||
| Ex-smoker, n (%) | 129 (26.1) | 30 (29.1) | 226 (27.1) | 44 (37.6) | 105 (32.1) | 20 (33.9) | |||
| Never smoked, n (%) | 278 (56.2) | 45 (43.7) | 456 (54.6) | 51 (43.6) | 160 (48.9) | 25 (42.4) | |||
| Employment status, n | 512 | 109 | .787 (CH) | 843 | 125 | .052 (CH) | 330 | 58 | .005 (CH) |
| Working full-time, n (%) | 333 (65.0) | 66 (60.6) | 461 (54.7) | 55 (44.0) | 207 (62.7) | 26 (44.8) | |||
| Working part-time, n (%) | 58 (11.3) | 11 (10.1) | 102 (12.1) | 25 (20.0) | 37 (11.2) | 4 (6.9) | |||
| On long-term sick leave, n (%) | 4 (0.8) | 1 (0.9) | 18 (2.1) | 5 (4.0) | 12 (3.6) | 7 (12.1) | |||
| Homemaker, n (%) | 25 (4.9) | 9 (8.3) | 58 (6.9) | 10 (8.0) | 18 (5.5) | 9 (15.5) | |||
| Student, n (%) | 41 (8.0) | 9 (8.3) | 110 (13.0) | 17 (13.6) | 19 (5.8) | 4 (6.9) | |||
| Retired, n (%) | 29 (5.7) | 6 (5.5) | 54 (6.4) | 4 (3.2) | 20 (6.1) | 5 (8.6) | |||
| Unemployed, n (%) | 22 (4.3) | 7 (6.4) | 40 (4.7) | 9 (7.2) | 17 (5.2) | 3 (5.2) | |||
| Duration of IBD, n | 479 | 99 | .488 (t-test) | 795 | 111 | .638 (t-test) | 314 | 55 | .245 (t-test) |
| Duration of IBD, years, mean (SD) | 4.4 (5.8) | 4.0 (5.4) | 5.3 (6.1) | 5.6 (6.5) | 10.0 (7.6) | 11.3 (9.0) | |||
| Current severity, n | 533 | 110 | <.001 (MW) | 868 | 126 | <.001 (MW) | 344 | 60 | <.001 (MW) |
| Mild, n (%) | 471 (88.4) | 70 (63.6) | 676 (77.9) | 67 (53.2) | 224 (65.1) | 24 (40.0) | |||
| Moderate/severe, n (%) | 62 (11.6) | 40 (36.4) | 192 (22.1) | 59 (46.8) | 120 (34.9) | 36 (60.0) | |||
| Current remission status, n | 199 | 49 | .147 (MW) | 218 | 38 | .038 (MW) | 91 | 30 | .060 (MW) |
| In remission, n (%) | 185 (93.0) | 42 (85.7) | 183 (83.9) | 26 (68.4) | 71 (78.0) | 18 (60.0) | |||
| Current flaring status, n | 478 | 103 | .250 (FE) | 801 | 115 | <.001 (FE) | 329 | 58 | <.001 (FE) |
| Flaring, n (%) | 26 (5.4) | 9 (8.7) | 40 (5.0) | 17 (14.8) | 25 (7.6) | 17 (29.3) | |||
| Current steroid use, n | 533 | 110 | <.001 (FE) | 868 | 126 | <.001 (FE) | 344 | 60 | .331 (FE) |
| Receiving steroids, n (%) | 105 (19.7) | 50 (45.5) | 44 (5.1) | 19 (15.1) | 28 (8.1) | 7 (11.7) | |||
| HCP visits, n | 333 | 82 | .575 (t-test) | 668 | 106 | .662 (t-test) | 279 | 49 | .984 (t-test) |
| HCP visits in past year, mean (SD) | 2.6 (4.4) | 2.9 (3.9) | 3.4 (4.7) | 3.6 (4.2) | 4.2 (5.9) | 4.2 (6.7) | |||
| Patient-reported | |||||||||
| EQ VAS, n | 217 | 55 | .122 (t-test) | 245 | 39 | .002 (t-test) | 97 | 30 | .718 (t-test) |
| EQ VAS, mean (SD) | 79.4 (12.8) | 76.3 (13.6) | 80.5 (15.6) | 71.6 (21.0) | 73.3 (20.8) | 71.8 (13.6) | |||
| WPAI, n | 125 | 29 | <.001 (t-test) | 121 | 17 | .373 (t-test) | 60 | 17 | .040 (t-test) |
| Overall work impairment, mean (SD) % | 11.9 (14.9) | 26.4 (17.5) | 17.0 (22.3) | 22.0 (15.6) | 17.2 (19.3) | 27.9 (16.2) | |||
| SIBDQ, n | 214 | 53 | <.001 (t-test) | 241 | 37 | .006 (t-test) | 96 | 30 | .003 (t-test) |
| SIBDQ total score, mean (SD) | 57.7 (10.8) | 49.0 (8.5) | 54.0 (12.3) | 47.9 (14.7) | 53.3 (12.4) | 45.4 (11.9) | |||
Abbreviations: BMI, body mass index; BU, bowel urgency; CH, χ2 test; EQ VAS, EuroQol visual analog scale; FE, Fisher’s exact test; HCP, healthcare practitioner; IBD, inflammatory bowel disease; MW, Mann–Whitney test; SD, standard deviation; SIBDQ, Short Inflammatory Bowel Disease Questionnaire; TT-naïve, patients who were currently receiving conventional therapy with a duration >3 months and had never received targeted therapy; 1L-TT, patients who were currently receiving their first targeted therapy with a duration >3 months; TT-exp, patients who were currently receiving their second or later targeted therapy with duration >3 months; WPAI, work productivity and activity impairment.